Roche Holding said its immunotherapy drug Tecentriq slowed the progression of lung cancer and helped patients live longer in a late-stage study, bolstering the Swiss drugmaker’s defense against a wave of cut-price competition to its top-selling medicines.

Sections:  world   
Topics:  europe   
RELATED ARTICLES
BING NEWS:
  • NHS patients barred from BMS' Opdivo, Roche's Kadcyla
    NICE is planning to bar patients with a particular form of lung cancer from access to Bristol-Myers Squibb’s ground-breaking immunotherapy Opdivo on the ... the Early Access to Medicines Scheme. The d...
    12/15/2015 - 5:45 pm | View Link
  • Roche's Ventana Collaborates with AstraZeneca's MedImmune
    The deal includes the MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay. The treatment is based on cancer immunotherapy which ... by the U.S. ...
    06/5/2014 - 12:02 pm | View Link
  • More
BING SEARCH:
  • Merck BMS Roche lung cancer immunotherapy data
    Among the 692 people who took part in the trial, those who received a combination of the company's immunotherapy drug, Tecentriq, one of its other cancer drugs, Avastin, and two chemotherapy drugs ...
    09/15/2018 - 11:54 pm | View Website
  • Two Roche Cancer Drugs Get Disappointing Results | BioSpace
    In one study, combining Roche's immunotherapy drug Tecentriq with other standard cancer drugs extended by only about three weeks the median time patients with advanced squamous cell lung cancer lived before their disease progressed.
    09/15/2018 - 11:23 am | View Website
  • Roche
    Oncology and cancer immunotherapy Innovation is at the core of Roche’s leading position in oncology. >10 . million cancer patients treated with Roche medicines
    09/11/2018 - 7:56 pm | View Website
  • Cancer immunotherapy drug TECENTRIQ extends lives of ...
    Cancer immunotherapy drug TECENTRIQ extends lives of patients with certain type of lung cancer. Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy
    09/5/2018 - 5:40 pm | View Website
  • Immunotherapy Drug Extended Patients’ Lives – LIVING CORAM DEO
    Immunotherapy Drug Extended Patients’ Lives. Roche Holding AG said 21 December that its immunotherapy drug Tecentriq slowed the progression of lung cancer and helped patients live longer in a late-stage study, offering new hope for patients and bolstering the Swiss drugmaker’s defence against a wave of cut-price competition to its top-selling medicines.
    08/30/2018 - 4:14 pm | View Website
  • More
Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News